1414 - Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia /small lymphocytic lymphoma in the phase 2 CAPTIVATE study

Primary Author(s)

CT

Constantine S. Tam, MD, MBBS

Consultant Haematologist
Alfred Hospital and Monash University
Melbourne, Victoria, Australia

Co-Author(s)

Paul M. Barr, MD

Professor of Medicine
Wilmot Cancer Institute / University of Rochester Medical Center
Rochester, New York, United States
John Allan, MD

Assistant Prof Medicine
Weill Cornell Medicine
New York, New York, United States
Tanya Siddiqi, MD

Professor
City of Hope Orange County
Irvine, California, United States
AT

Alessandra Tedeschi, MD

ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
Thomas J. Kipps, MD, PhD

Distinguished Professor of Medicine, Co-Director, Hematology Malignancy Program; Director, Center for Novel Therapies; Evelyn and Edwin Tasch Chair in Cancer Research
UC San Diego, Moores Cancer Center
San Diego, California, United States
SO

Susan O’Brien, MD

UC Irvine, Chao Family Comprehensive Cancer Center
Irvine, California, United States
Ryan Jacobs, MD

Assistant Professor
Department of Hematology, Lymphoma Division, Levine Cancer Institute/Atrium Health
Charlotte, North Carolina, United States
XB

Xavier C. Badoux, MBBS,FRACP, FRCPA

Ministry of Health
Kogarah, New South Wales, Australia
LT

Livio Trentin, MD

Hematology Unit, University of Padova
Padova, Veneto, Italy
ML

Masa Lasica, MBBS, BMedSci, FRACP, FRCPA

Clinical Haematologist
St Vincent's Hospital Melbourne
Melbourne, Victoria, Australia
DC

Dennis Carney, MBBS, FRACP, FRCPA

Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
AE

Anna Elinder Camburn, MBChB, FRACP, FRCPA

North Shore Hospital
Takapuna, Auckland, New Zealand
Javier de la Serna, MD

Servicio de Hematologia
Hospital Universitario 12 de Octubre
Madrid, Spain
ES

Edith Szafer- Glusman, PhD

AbbVie Inc.
Chicago, Illinois, United States
CZ

Cathy Zhou, MS

AbbVie
Chicago, Illinois, United States
JN

Jutta K. Neuenburg, MD, PhD

AbbVie Inc.
Chicago, Illinois, United States
James P. Dean, MD, PhD

Executive Medical Director Oncology
AbbVie Inc.
North Chicago, Illinois, United States
Paolo Ghia, MD, PhD

Professor of Medical Oncology
Università Vita Salute and IRCCS Ospedale San Raffaele
Milano, Lombardia, Italy

Co-Author / Presenter(s)

WW

William G. Wierda, MD, PhD

Professor of Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States